Pat Mallon has extensive senior and C-level executive experience in the bio/pharmaceutical, medical device and life sciences industries with expertise in the conceptualization, development and commercialization of new, cutting-edge technologies, services, and products. He has a successful track record in building organizations in both start-up and Fortune 500 companies including founding five companies and one investment fund.
Mallon was integral in the development and commercialization of the Nobel Prize-winning PCR technology and introduction of the world’s first protease inhibitor for HIV disease. Also, he has been responsible for product sales ranging from inception to over $1 billion annually. Additionally, he has led and/or participated in negotiating and structuring numerous transactions, including the raising of over $80 million in venture capital, greater than $500 million in strategic partnerships and licenses, and over $5 billion in M&A transactions.
Currently, Mallon is the COO of Polynoma, LLC, a development-stage immuno-oncology company, and a Board Director (founder and interim CEO) of a genomics-based precision medicine start-up. Mallon holds a Bachelor’s degree in Medical Technology from The University of Arizona.